Lenalidomide Sun

Lenalidomide, the active ingredient in Lenalidomide Sun, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies.

- Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients. - Myelodysplastic Syndromes: reduces transfusion dependence and delays transformation to acute leukemia. - Mantle Cell Lymphoma: enhances response when combined with standard chemotherapy in relapsed or refractory disease.

Lenalidomide may cause a range of adverse reactions.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet count leading to easy bruising. - Anemia: decreased red blood cells causing weakness. - Constipation: infrequent bowel movements. - Rash: mild skin irritation or redness.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: profound immune suppression requiring medical intervention. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: liver enzyme elevations or liver injury. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Before initiating therapy, several safety considerations are essential.

- Pregnancy: contraindicated (Category X); avoid use in pregnant women. - Thrombosis risk: assess for prior clotting events and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular CBCs to detect neutropenia, thrombocytopenia, or anemia. - Renal/hepatic function: adjust therapy in patients with impaired kidney or liver function. - Drug interactions: review concomitant medications for potential additive toxicity. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Lenalidomide interacts with several drug classes that may alter its safety or efficacy.

Major Interactions (Avoid): - Thalidomide: combined use increases teratogenic and neurotoxic risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise lenalidomide plasma levels. - Live vaccines: may cause uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): heightened risk of thromboembolic events. - NSAIDs: may exacerbate hematologic toxicity, especially neutropenia.